International Journal of Cardiology
Volume 139, Issue 1 , Pages 32-41 , 18 February 2010

The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors

  • Christian F. Rueda-Clausen

      Affiliations

    • Grupo Vía L-Arginina Óxido Nítrico VILANO, Fundación Cardiovascular de Colombia / Floridablanca, Colombia
    • Departamento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid / Madrid, Spain
    • Current address: 232 HMRC, University of Alberta, Edmonton AB., Canada T6G 2S2.
    • ,
  • Vicente Lahera

      Affiliations

    • Departamento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid / Madrid, Spain
    • ,
  • Jaime Calderón

      Affiliations

    • Grupo de Cirugía Cardiovascular QUIRON, Fundación Cardiovascular de Colombia / Floridablanca, Colombia
    • ,
  • Isabel Cristina Bolivar

      Affiliations

    • Grupo Vía L-Arginina Óxido Nítrico VILANO, Fundación Cardiovascular de Colombia / Floridablanca, Colombia
    • ,
  • Victor R. Castillo

      Affiliations

    • Grupo de Cirugía Cardiovascular QUIRON, Fundación Cardiovascular de Colombia / Floridablanca, Colombia
    • ,
  • Melquisedec Gutiérrez

      Affiliations

    • Grupo de Cirugía Cardiovascular QUIRON, Fundación Cardiovascular de Colombia / Floridablanca, Colombia
    • ,
  • Marisol Carreño

      Affiliations

    • Grupo de Cirugía Cardiovascular QUIRON, Fundación Cardiovascular de Colombia / Floridablanca, Colombia
    • ,
  • Maria del Pilar Oubiña

      Affiliations

    • Departamento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid / Madrid, Spain
    • ,
  • Victoria Cachofeiro

      Affiliations

    • Departamento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid / Madrid, Spain
    • ,
  • Patricio López-Jaramillo

      Affiliations

    • Grupo Vía L-Arginina Óxido Nítrico VILANO, Fundación Cardiovascular de Colombia / Floridablanca, Colombia
    • Dirección de Investigaciones, Facultad de Medicina, Universidad de Santander, Bucaramanga, Colombia
    • Corresponding Author InformationCorresponding author. Calle 155a # 23 – 58, Third Floor, Floridablanca, Santander, Colombia. Tel.: +57 7 6399292x340, 343; fax: +57 7 6392744.

Received 4 February 2008 ,Revised 9 August 2008 ,Accepted 2 September 2008.

References 

  1. Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol. 2003;35:826–837
  2. Meyers MR, Gokce N. Endothelial dysfunction in obesity: etiological role in atherosclerosis. Curr Opin Endocrinol Diabetes Obes. 2007;14:365–369
  3. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968–976
  4. Scaglione R, Argano C, Di Chiara T, Licata G. Obesity and cardiovascular risk: the new public health problem of worldwide proportions. Expert Rev Cardiovasc Ther. 2004;2:203–212
  5. International Diabetes Federation . The IDF consensus worldwide definition of the metabolic syndrome [article online]. 2005;Available from http://www.idf.org/webdata/docs/metac_syndrome_def.pdf. 2005
  6. Kahn R, Buse J, Ferrannini E, Stern M. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–2304
  7. Reaven GM. The metabolic syndrome: is this diagnosis necessary?. Am J Clin Nutr. 2006;83:1237–1245
  8. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet. 2005;366:1640–1649
  9. Despres JP. Health consequences of visceral obesity. Ann Med. 2001;33:534–541
  10. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002;40:937–943
  11. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism. 2004;53:495–499
  12. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–887
  13. Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007;30:1647–1652
  14. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21:1–6
  15. Perez M, Casas JP, Cubillos-Garzon LA, et al. Using waist circumference as a screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2003;10:328–335
  16. Garcia RG, Cifuentes AE, Caballero RS, Sanchez L, Lopez-Jaramillo P. A proposal for an appropriate central obesity diagnosis in Latin American population. Int J Cardiol. 2006;110:263–264
  17. Lopez-Jaramillo P, Rueda-Clausen CF, Silva FA. The utility of different definitions of metabolic syndrome in Andean population. Int J Cardiol. 2007;116:421–422
  18. Lohman T, Roche A, Martorel R. Standarisation of antropometric measurements. In: The airline (VA) Concensus Conference ChampaingIII: Human Kinetics. 1988;
  19. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42:76–81
  20. Oubina MP, de las HN, Cediel E, et al. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clin Sci (Lond). 2003;105:655–662
  21. Despres JP. Is visceral obesity the cause of the metabolic syndrome?. Ann Med. 2006;38:52–63
  22. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol. 1997;273:E425–E432
  23. Chandalia M, Abate N, Garg A, Stray-Gundersen A, Grundy SM. Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84:2329–2335
  24. Moncada S, Higgs EA, Hodson HF, et al. The L-arginine: nitric oxide pathway. J Cardiovasc Pharmacol. 1991;17:S1–S9
  25. Steinberg HO, Chaker H, Leamin R. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest. 1996;97:2601–2610
  26. Lakka TA, Lakka HM, Salonen R, Kaplan GA, Salonen JT. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis. 2001;154:497–504
  27. Wei W, Zhi-Wu C, Qin Y, et al. Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery. Vasc Pharmacol. 2007;46:253–259
  28. Meyer AA, Kundt G, Steiner M, Schuff-Werner P, Kienast W. Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors. Pediatrics. 2006;117:1560–1567
  29. Siddiqui AH, Hussain T. Enhanced AT1 receptor-mediated vasocontractile response to ANG II in endothelium-denuded aorta of obese Zucker rats. Am J Physiol Heart Circ Physiol. 2007;292:H1722–H1727
  30. Ahima RS. Adipose tissue as an endocrine organ. Obesity. 2006;5:242S–249S
  31. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine. 2006;29:81–90
  32. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;49:9–14
  33. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–89
  34. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189:47–60
  35. Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci. 2001;147:141–150
  36. Ustundag B, Gungor S, Aygun AD, Turgut M, Yilmaz E. Oxidative status and serum leptin levels in obese prepubertal children. Cell Biochem Funct. 2007;25:479–483
  37. Zeidan A, Purdham DM, Rajapurohitam V, Javadov S, Chakrabarti S, Karmazyn M. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther. 2005;315:1075–1084
  38. Cabrera MA, Gebara OC, Diament J, Nussbacher A, Rosano G, Wajngarten M. Metabolic syndrome, abdominal obesity, and cardiovascular risk in elderly women. Int J Cardiol. 2007;114:224–229
  39. Campia U, Choucair WK, Bryant MB, Quyyumi AA, Cardillo C, Panza JA. Role of cyclooxygenase products in the regulation of vascular tone and in the endothelial vasodilator function of normal, hypertensive and hypercholesterolemic humans. Am J Cardiol. 2002;89:286–290
  40. Bulut D, Liaghat S, Hanefeld C, Koll R, Miebach T, Mugge A. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens. 2003;21:1663–1667
  41. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(08)01012-7

doi: 10.1016/j.ijcard.2008.09.005

International Journal of Cardiology
Volume 139, Issue 1 , Pages 32-41 , 18 February 2010

Article Tools

* Image Usage & Resolution